Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need

Time: 2:30 pm
day: Day Two


  • Which of the current state of the art immunotherapies are likely to combine well with neoantigen therapies?
  • Beyond checkpoint inhibitors, what combinations seem the most promising?
  • Are there certain combinations which work better for different stages of cancer?
  • Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins.